CYTEA|BIO is a preclinical-stage biotechnology company focusing on allogeneic cellular immunotherapies. The company has developed and patented the Pin™ platform, a versatile and modular cell therapy platform enabling the combination of unmodified immune effector cells (such as NK cells and macrophages) with targeting ligands. CYTEA|BIO is the first pipeline company of MedXCell, a European cell therapy venture builder with offices in Switzerland, France and the US. MedXCell focuses on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders, with the aim to turn promising academic ideas into commercially viable propositions.